NYLIM
BIO icon

New York Life Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

New York Life Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$334K Sell
1,139
-1,094
-49% -$310K ﹤0.01% 768
2026
Q1 		$622K Buy
2,233
+579
+35% +$167K 0.01% 739
2025
Q4 		$501K Buy
+1,654
New +$516K ﹤0.01% 722
2024
Q4 		– Sell
-1,879
Closed -$629K – 824
2024
Q3 		$629K Sell
1,879
-866
-32% -$275K 0.01% 791
2024
Q2 		$750K Sell
2,745
-55
-2% -$16K 0.01% 743
2024
Q1 		$968K Sell
2,800
-107
-4% -$35.2K 0.01% 680
2023
Q4 		$939K Sell
2,907
-18
-0.6% -$5.64K 0.01% 674
2023
Q3 		$1.05M Sell
2,925
-44
-1% -$17K 0.01% 619
2023
Q2 		$1.13M Sell
2,969
-151
-5% -$61.4K 0.01% 587
2023
Q1 		$1.49M Buy
3,120
+134
+4% +$62.7K 0.02% 561
2022
Q4 		$1.26M Sell
2,986
-83
-3% -$33.5K 0.01% 596
2022
Q3 		$1.28M Sell
3,069
-22
-0.7% -$11K 0.02% 584
2022
Q2 		$1.53M Buy
+3,091
New +$1.61M 0.02% 557

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

New York Life Investment Management's BIO Position: Q2 2026 in Review

New York Life Investment Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 49% in Q2 2026, selling an estimated $310K and leaving 1,139 shares worth $334K. The position accounts for ﹤0.01% of the portfolio, ranked #768.

New York Life Investment Management first reported a position in BIO in Q2 2022 and has held it in 13 quarters since. The position peaked at $1.53M in Q2 2022. 190 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • New York Life Investment Management held 1,139 shares of Bio-Rad Laboratories Class A worth $334K as of Q2 2026.
  • New York Life Investment Management sold 1,094 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $310K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of New York Life Investment Management's portfolio in Q2 2026, its #768 holding.
  • New York Life Investment Management first reported a position in Bio-Rad Laboratories Class A in Q2 2022 and has held it in 13 quarters since.
  • New York Life Investment Management's Bio-Rad Laboratories Class A position peaked at $1.53M in Q2 2022.
  • 190 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.